B-cell Acute Lymphoblastic Leukemia

Pediatric Oncology NCI Standard risk B-cell Acute Lymphoblastic Leukemia – Ten year outcome from India. Where are we heading towards?
Annapoorani Ramasamy • Venkateshwaran VS
doi.org/10.69690/ODMJ-018-0425-2468
Pediatric Oncology CD19 Chimeric Antigen Receptor (CAR) T – Cell therapy with Tisagenlecleucel in Children with B-Cell Acute Lymphoblastic Leukemia: Preliminary Findings from a Tertiary Care Center
Nada Alshaikh • Rodaina Abujoub • Rimaz Mustafa • Shahbaz Memon • Ahmed Mahdi Yousif • Sami AlThubaiti • Mohammed Essa
doi.org/10.69690/ODMJ-018-0425-2157
Pediatric Oncology Prognostic Significance of CD79a Expression in Paediatric B-Cell Acute Lymphoblastic Leukaemia: Implications for Risk Stratification and Therapeutic Targeting
Muhammad Alsabagh • Asmaa Hamoda • Eman Kandel • Sally Talaat
doi.org/10.69690/ODMJ-018-0425-378